Clinical

Dataset Information

0

Study of NKTR 255 in Combination With Cetuximab in Solid Tumors


ABSTRACT: This is a Phase 1b/2, open-label multicenter study evaluating NKTR-255 as a monotherapy and together with cetuximab in patients with head and neck squamous cell carcinoma (HNSCC), colorectal carcinoma (CRC), cutaneous squamous cell carcinoma (cSCC), anal cell carcinoma (ASCC) and cervical cancer. The recommended phase 2 dose of NKTR-255, determined in the dose escalation phase (Phase 1b), will be used to treat patients in Phase 2 of this study.

DISEASE(S): Uterine Cervical Neoplasms,Carcinoma,Cervical Cancer,Colon Carcinoma Recurrent,Colorectal Cancer,Relapsed Or Refractory (r/r) Head And Neck Squamous Cell Carcinoma (hnscc) Or Colorectal Carcinoma (crc),Cutaneous Squamous Cell Carcinoma,Anal Squamous Cell Carcinoma,Carcinoma, Squamous Cell,Squamous Cell Carcinoma Of Head And Neck,Squamous Cell Carcinoma Of Head And Neck Metastatic,Colorectal Neoplasms,Head And Neck Squamous Cell Carcinoma,Carcinoma Escamoso De Cabeza Y Cuello (cecc) O Carcinoma Colorrectal (ccr) Recidivante O Resistente (r/r),Carcinoma Colon Recurrent

PROVIDER: 2356733 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2024-08-14 | GSE273138 | GEO
2018-09-19 | PXD009241 | Pride
2017-03-30 | E-MTAB-5198 | biostudies-arrayexpress
2011-02-16 | E-GEOD-27333 | biostudies-arrayexpress
2011-09-14 | E-GEOD-32115 | biostudies-arrayexpress
2014-10-02 | E-GEOD-36110 | biostudies-arrayexpress
2023-10-21 | PXD033023 | Pride
2018-04-06 | GSE112743 | GEO
2016-01-14 | E-MTAB-3670 | biostudies-arrayexpress
| PRJNA844527 | ENA